Maria Beconi

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes

George R. Lankas, Barbara Leiting, Ranabir Sinha Roy et al. · Diabetes · 2005 · 491 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease

Roland W. Bürli, Christopher A. Luckhurst, Omar Aziz et al. · Journal of Medicinal Chemistry · 2013 · 149 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

(2<i>S</i>,3<i>S</i>)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-<i>N,N</i>-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-<i>a</i>]- pyridin-6-ylphenyl)butanamide:  A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Scott D. Edmondson, Anthony Mastracchio, Robert J. Mathvink et al. · Journal of Medicinal Chemistry · 2006 · 121 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors

Scott D. Edmondson, Lan Wei, Jinyou Xu et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 110 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14